Oculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline Assets

Core Insights - Oculis Holding AG is hosting an R&D Day to update on its late-stage clinical candidates and future development strategies [1][2] - The event will feature key opinion leaders and will include a live Q&A session [2][3] Company Overview - Oculis is a global biopharmaceutical company focused on ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs [5] - The company has a differentiated pipeline including OCS-01 for diabetic macular edema, Privosegtor for acute optic neuritis, and Licaminlimab for dry eye disease [5] Clinical Development Updates - Enrollment for the Phase 3 DIAMOND trials of OCS-01 has been completed with over 800 patients, and topline data is expected in Q2 2026 [6] - Licaminlimab's Phase 2/3 study is anticipated to start in the second half of 2025, focusing on a personalized approach to dry eye disease [6] - Expanded data analysis from the ACUITY Phase 2 trial for Privosegtor will be discussed, along with new programs for treating non-arteritic anterior ischemic optic neuritis and multiple sclerosis [6]